Compare Davita Inc (DVA) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Hut 8 Corp — how do they compare? Davita Inc trades at $179.24 (market cap $11.29B), while Hut 8 Corp trades at $80.97 (market cap $9.82B). The key difference: Davita Inc and Hut 8 Corp are close in size by market cap, and Davita Inc is more actively traded (582,204 versus 10,272,678). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Hut 8 Corp for 11 Days on average.
| DVA | HUT | |
|---|---|---|
Market Cap | $11.29B | $9.82B |
Volume | 582,204 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $240.96 | $133.02 |
52-Week Low | $103.87 | $33.76 |
Typical Hold Time | 113 Days | 11 Days |
Enterprise Value | $24.01B | $17.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
HUT's stock trades at $80.25, down 10.13% over 24 hours, reflecting bearish technical signals amid weak financials. The company reported a net loss of $226.15 million for 2025, with negative cash flow from operations, though it secured a $1.07 billion credit facility to bolster liquidity. Analyst consensus remains strongly bullish with a $162.69 price target, driven by optimism around its AI infrastructure contracts.
The outlook hinges on HUT's ability to monetize its AI data center pipeline and achieve profitability. Key risks include persistent losses, high debt levels, and execution challenges in a competitive market. The stock offers high-reward potential if the company delivers on its growth strategy, but investors face significant downside if operational improvements falter.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
